Bachem Holding AG (BANB.SW)
Bachem Holding AG (BANB.SW)
One-line summary: World's largest pure-play peptide API CDMO and the highest-conviction listed beneficiary of GLP-1 scale-up — FY2025 CHF 695M (+14.8% YoY), targeting CHF 1B+ in 2026.
What it is
Swiss peptide contract development and manufacturing organization (CDMO). Manufactures peptide active pharmaceutical ingredients (APIs) via solid-phase peptide synthesis (SPPS) — the specialized chemistry required to produce semaglutide, tirzepatide, and all other GLP-1 injectable drugs. Cannot be repurposed from standard pharma manufacturing: SPPS requires large-scale specialized reactors, purification, and freeze-drying infrastructure.
Why it matters to stock-market
Bachem is the most direct listed pick-and-shovel play on injectable GLP-1 scale-up. As Novo Nordisk and Eli Lilly push volumes toward hundreds of millions of doses annually, the rate-limiting step is validated peptide API supply — and Bachem dominates that step. The company's Building K (new large-scale SPPS facility) is the key catalyst for the 2026 CHF 1B+ revenue target.
US access is thin: no liquid US ADR (BANB.SW is Swiss-listed). This limits the US institutional investor base and creates execution friction.
Key facts
- FY2025 revenue: CHF 695.1M (+14.8% YoY; +19.2% in local currencies). H1 2025: CHF 313M (+30.2% vs H1 2024); EBITDA margin 29.1% (up from 23.1%). From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- 2026 target: >CHF 1 billion revenue, >30% EBITDA margin — a 65%+ two-year revenue growth trajectory. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- Building K (new large-scale SPPS facility): Phase 1 inspected by Swissmedic at end-2025; commercial production ramping in 2026. Phase 2 still under construction — the key enabler for the 2026 revenue target. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- Market context: Peptide API market volume projected to grow from 265 metric tonnes (2025) to 855 MT by 2031 at 21.72% CAGR. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
Strengths
- Dominant market position in peptide API for injectable GLP-1s — structural not cyclical advantage
- High EBITDA margins (29%+) supported by proprietary SPPS capacity and demand scarcity
- Building K ramp provides multi-year revenue visibility
Risks
- Swiss-listed only (BANB.SW) — no liquid US ADR; execution friction limits US investor base
- Oral GLP-1 risk: orforglipron (Eli Lilly Foundayo) is a non-peptide small molecule requiring no SPPS; if oral GLP-1 captures >30% of market, demand for Bachem's specific SPPS capability could plateau
- CHF/USD currency risk (CHF is strong safe-haven currency)